FRANKFURT, July 28 (Reuters) - The EU's trade deal with the United States represents a setback for global healthcare provision and Europe as an innovation hub from the perspective of research-based pharmaceutical companies, Germany's vfa association said on Monday.
"This deal breaks with the foundations of transatlantic trade, undermines World Trade Organization rules, and ends the achievement of free trade in medicines," said Han Steutel, president of the German Pharmaceutical Industry Association (vfa).